New Trial Data Show Hair Growth in More Alopecia Areata Patients

[Srijit]

Nearly 40% of adults with alopecia areata taking baricitinib, an oral Janus kinase (JAK) 1 and 2 inhibitor, see significant hair regrowth over 52 weeks, according to updated results from two phase 3 trials presented at the American Academy of Dermatology 2022 annual meeting in Boston, Massachusetts. The results indicate improved response rates and hair growth among trial participants, said Brett King, MD, PhD, an associate professor of dermatology at the Yale University School of Medicine in New Haven, Connecticut. He is the lead author of the analyses and presented the research.

[Ayra]

@srijit The researchers pooled data from both clinical trials, with a combined enrollment of 1200, for the 52-week results presented at the meeting. The placebo group stopped at 36 weeks, and these patients were randomly reassigned to either the 4-mg or 2-mg once-daily baricitinib treatment groups.